Student or educator? Sign up with your school email and get 6 months of Pro free.
Cited by 182

The DOI matches its Crossref record; 8 of the 8 references it cites were found in a registry or an index.

MET Inhibitors Promote Liver Tumor Evasion of the Immune Response by Stabilizing PDL1

Open access
Li, Hui, Li, Chia-Wei, Li, Xiaoqiang, Ding, Qingqing, Guo, Lei, Liu, Shuang, Liu, Chunxiao, Lai, Chien-Chen, Hsu, Jung-Mao, Dong, Qiongzhu, Xia, Weiya, Hsu, Jennifer L., Yamaguchi, Hirohito, Du, Yi, Lai, Yun-Ju, Sun, Xian, Koller, Paul B., Ye, Qinghai, Hung, Mien-Chie·2019·Gastroenterology

Abstract

BACKGROUND & AIMS: Inhibitors of MET have not produced satisfactory outcomes in trials of patients with liver cancer. We investigated the mechanisms of liver tumor resistance to MET inhibitors in mice. METHODS: We tested the effects of MET inhibitors tivantinib and capmatinib in the mouse hepatocellular carcinoma (HCC) cell line HCA-1 and in immune-competent and immunodeficient mice with subcutaneous tumors grown from this cell line. Tumors were collected from mice and tumor cells were analyzed by time-of-flight mass cytometry. We used short hairpin RNAs to weaken expression of MET in Hep3B, SK-HEP-1, HA59T, and HA22T liver cancer cell lines and analyzed cells by immunoblot, immunofluorescence, and immunoprecipitation assays. Mass spectrometry was used to assess interactions between MET and glycogen synthase kinase 3β (GSK3B), and GSK3B phosphorylation, in liver cancer cell lines. C57/BL6 mice with orthotopic tumors grown from Hep1-6 cells were given combinations of capmatinib or tivantinib and antibodies against programmed cell death 1 (PDCD1; also called PD1); tumors were collected and analyzed by immunofluorescence. We analyzed 268 HCCsamples in a tissue microarray by immunohistochemistry. RESULTS: Exposure of liver cancer cell lines to MET inhibitors increased their expression of PD ligand 1 (PDL1) and inactivated cocultured T cells. MET phosphorylated and activated GSK3B at tyrosine 56, which decreased the expression of PDL1 by liver cancer cells. In orthotopic tumors grown in immune-competent mice, MET inhibitors decreased the antitumor activity of T cells. However, addition of anti-PD1 decreased orthotopic tumor growth and prolonged survival of mice compared with anti-PD1 or MET inhibitors alone. Tissue microarray analysis of HCC samples showed an inverse correlation between levels of MET and PDL1 and a positive correlation between levels of MET and phosphorylated GSK3B. CONCLUSIONS: In studies of liver cancer cell lines and mice with orthotopic tumors, MET mediated phosphorylation and activated GSK3B, leading to decreased expression of PDL1. Combined with a MET inhibitor, anti-PD1 and anti-PDL1 produced additive effect to slow growth of HCCs in mice.

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1053/j.gastro.2019.01.252

Cites

8 of 8 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 8 references

Cited by

See all 182

Metadata

Authors
Li, H., Li, C.-W., Li, X., Ding, Q., Guo, L., Liu, S., Liu, C., Lai, C.-C., Hsu, J.-M., Dong, Q., Xia, W., Hsu, J. L., Yamaguchi, H., Du, Y., Lai, Y.-J., Sun, X., Koller, P. B., Ye, Q., & Hung, M.-C.
Venue
Gastroenterology
Publisher
Elsevier BV
Published
2019-05
Volume
156
Issue
6
Pages
1849-1861.e13
ISSN
0016-5085 (ISSN-L)
OpenAlex
W2914108153
Cited by
182
References
8
FWCI
9.79
Type
journal article
Language
en
Open access
bronze

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: MET Inhibitors Promote Liver Tumor Evasion of the Immune Response by Stabilizing PDL1. https://app.cochat.ai/papers/10.1053/j.gastro.2019.01.252
The paper
Li, H., Li, C.-W., Li, X., Ding, Q., Guo, L., Liu, S., Liu, C., Lai, C.-C., Hsu, J.-M., Dong, Q., Xia, W., Hsu, J. L., Yamaguchi, H., Du, Y., Lai, Y.-J., Sun, X., Koller, P. B., Ye, Q., & Hung, M.-C. (2019). MET Inhibitors Promote Liver Tumor Evasion of the Immune Response by Stabilizing PDL1. Gastroenterology. https://doi.org/10.1053/j.gastro.2019.01.252

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.